Pharmaceuticals, Biotechnology and Life Sciences
Gossamer Bio has reported a net loss for the first quarter 2020, was $54.1 million, or $0.87 per share, compared to a net loss of $32.6 million, or $0.90 per share, for the same period in 2019, while cash, cash equivalents and marketable securities totaled $346 million as of March 31, 2020.
Catabis expects top-line results in Q4 2020 from fully enrolled edasalonexent global phase 3 PolarisDMD trial in duchenne muscular dystrophy.
PhaseBio reported a net loss of $14.9 million for the three months ended March 31, 2020, which compared with a net loss of $7.3 million for the same period in 2019, which resulted in a net loss of $0.52.
Moderna has received FDA’s fast track designation for mRNA-1273 vaccine against the novel coronavirus, with finalizing protocol for Phase 3 study of mRNA-1273, expected to begin in early summer of 2020.
“When Sarclisa was added to standard-of-care treatment carfilzomib and dexamethasone in this phase 3 trial, results clearly demonstrated a significant reduction in risk of disease progression or death, ” said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi.
FARGO, N.D.–(BUSINESS WIRE)–#Aldevron–Aldevron, the leading plasmid DNA manufacturing company, has expanded its leadership team by appointing Dr. James Brown President…
DENVER–(BUSINESS WIRE)–ClinOne is expanding its strategic collaboration with BioIntelliSense to combine continuous health monitoring and clinical intelligence with the ClinOne…
Pfizer invites investors and the general public to listen to a webcast of a discussion with Charles Triano, Senior Vice President, Investor Relations
Cooley lawyers working in the technology and life sciences industries have been advising some of the world’s most innovative companies as they seek to deliver products and services to battle myriad aspects of the COVID-19 pandemic.
Seattle Genetics gets first approval for Tukysa outside of the U.S., Switzerland’s first approval under FDA initiative project orbis.